论文部分内容阅读
慢性乙型肝炎(CHB)的治疗目标是最大限度地长期抑制或消除乙型肝炎病毒(HBV),减轻肝细胞炎症坏死以及肝纤维化,延缓和阻止疾病进展,减少和防止肝脏失代偿、肝硬化、肝癌及其并发症的发生,从而改善生活质量和延长存活时间。目前用于慢性乙型肝炎抗病毒治疗的药物有两类,即α干扰素(包括普通干扰素和聚乙二醇干扰素)和核苷(酸)类似物(包括拉米夫定、阿德福韦酯、替比夫定、恩替卡韦)。对于这些药物的临床应用已积累了许多符合循证医学要求的数据,因此国内外众多治疗指南或专家共识相继出台。本文试图依据上述指南和专家共识,就慢性乙型肝炎患者抗病毒治疗的注意事项作以综述。
Chronic hepatitis B (CHB) treatment goal is to maximize the long-term suppression or elimination of Hepatitis B virus (HBV), reduce inflammation and necrosis of liver cells and liver fibrosis, delay and prevent disease progression, reduce and prevent liver decompensation, Cirrhosis, liver cancer and its complications, thus improving the quality of life and prolonging the survival time. At present, there are two types of drugs for antiviral treatment of chronic hepatitis B, that is, interferon alpha (including common interferon and pegylated interferon) and nucleoside (acid) analogs (including lamivudine, Fu Wei ester, telbivudine, entecavir). For the clinical application of these drugs has accumulated a lot of evidence-based medical requirements of the data, so many domestic and international treatment guidelines or expert consensus have been introduced. This article attempts to review the precautions for antiretroviral therapy in patients with chronic hepatitis B based on these guidelines and expert consensus.